These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29503155)

  • 21. Aceruloplasminemia presenting with microcytic anemia in a Turkish boy due to a novel pathogenic variant.
    Gok V; Ozcan A; Ozer S; Karaman F; Aykutlu E; Yilmaz E; Karakukcu M; Bisgin A; Unal E
    Pediatr Hematol Oncol; 2023; 40(7):673-681. PubMed ID: 36308763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.
    Suzuki Y; Yoshida K; Aburakawa Y; Kuroda K; Kimura T; Terada T; Kono S; Miyajima H; Yahara O
    Intern Med; 2013; 52(13):1527-30. PubMed ID: 23812204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosing aceruloplasminemia: navigating through red herrings.
    Kharel Z; Kharel H; Phatak PD
    Ann Hematol; 2024 Jun; 103(6):2173-2176. PubMed ID: 38637332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis.
    Xu X; Pin S; Gathinji M; Fuchs R; Harris ZL
    Ann N Y Acad Sci; 2004 Mar; 1012():299-305. PubMed ID: 15105274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The copper-iron connection: hereditary aceruloplasminemia.
    Nittis T; Gitlin JD
    Semin Hematol; 2002 Oct; 39(4):282-9. PubMed ID: 12382203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extending the aceruloplasminemia phenotype: NBIA on imaging and acanthocytosis, yet only minor neurological findings.
    Kassubek R; Uttner I; Schönfeldt-Lecuona C; Kassubek J; Connemann BJ
    J Neurol Sci; 2017 May; 376():151-152. PubMed ID: 28431603
    [No Abstract]   [Full Text] [Related]  

  • 27. New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients.
    Vroegindeweij LHP; Langendonk JG; Langeveld M; Hoogendoorn M; Kievit AJA; Di Raimondo D; Wilson JHP; Boon AJW
    Parkinsonism Relat Disord; 2017 Mar; 36():33-40. PubMed ID: 28012953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seizures in Hereditary Aceruloplasminemia.
    Marano M; Bove F; Ricci L; Rohani M; Di Lazzaro V; Assenza G; Fasano A
    Can J Neurol Sci; 2021 Jan; 48(1):144-147. PubMed ID: 32741407
    [No Abstract]   [Full Text] [Related]  

  • 29. Aceruloplasminemia.
    Kono S
    Curr Drug Targets; 2012 Aug; 13(9):1190-9. PubMed ID: 22515740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and pathological basis of aceruloplasminemia.
    Kono S; Miyajima H
    Biol Res; 2006; 39(1):15-23. PubMed ID: 16629161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Central diabetes insipidus and hypothalamic hypothyroidism associated with aceruloplasminemia.
    Watanabe M; Asai C; Ishikawa K; Kiyota A; Terada T; Kono S; Miyajima H; Okumura A
    Intern Med; 2010; 49(15):1581-5. PubMed ID: 20686294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
    Lindner U; Schuppan D; Schleithoff L; Habeck JO; Grodde T; Kirchhof K; Stoelzel U
    Horm Metab Res; 2015 Apr; 47(4):303-8. PubMed ID: 25089372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A New Pathogenic Missense Variant in a Consanguineous North-African Family Responsible for a Highly Variable Aceruloplasminemia Phenotype: A Case-Report.
    Lobbes H; Reynaud Q; Mainbourg S; Savy-Stortz C; Ropert M; Bardou-Jacquet E; Durupt S
    Front Neurosci; 2022; 16():906360. PubMed ID: 35585918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia.
    Badat M; Kaya B; Telfer P
    Br J Haematol; 2015 Nov; 171(3):430-2. PubMed ID: 25855051
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia.
    Hofmann WP; Welsch C; Takahashi Y; Miyajima H; Mihm U; Krick C; Zeuzem S; Sarrazin C
    Scand J Gastroenterol; 2007 Sep; 42(9):1088-94. PubMed ID: 17710675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis.
    Harris ZL; Klomp LW; Gitlin JD
    Am J Clin Nutr; 1998 May; 67(5 Suppl):972S-977S. PubMed ID: 9587138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aceruloplasminaemia: a rare but important cause of iron overload.
    Doyle A; Rusli F; Bhathal P
    BMJ Case Rep; 2015 May; 2015():. PubMed ID: 25976187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients.
    Xu WQ; Ni W; Wang RM; Dong Y; Wu ZY
    Metab Brain Dis; 2021 Dec; 36(8):2273-2281. PubMed ID: 34347207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia.
    Kono S; Suzuki H; Takahashi K; Takahashi Y; Shirakawa K; Murakawa Y; Yamaguchi S; Miyajima H
    Gastroenterology; 2006 Jul; 131(1):240-5. PubMed ID: 16831606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aceruloplasminemia: A Severe Neurodegenerative Disorder Deserving an Early Diagnosis.
    Marchi G; Busti F; Lira Zidanes A; Castagna A; Girelli D
    Front Neurosci; 2019; 13():325. PubMed ID: 31024241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.